Hemispherx Biopharma, Inc.
One Penn Center
1617 JFK Boulevard
Philadelphia,
PA 19103
United States - Map
Phone: 215-988-0080
Fax: 215-988-1739
Web Site: http://www.hemispherx.net
| Hemispherx Biopharma, Inc., a biopharmaceutical company, engages in the clinical development, manufacture, marketing, and distribution of new drug therapies for the treatment of viral and immune based chronic disorders. The companys products include Alferon N Injection for the treatment of genital warts; and Ampligen, an experimental drug that is in human clinical development for the treatment of myalgic encephalomyelitis/chronic fatigue syndrome, HIV, renal cell carcinoma, and malignant melanoma. Its products also comprise Alferon LDO, a low-dose, oral liquid formulation of natural alpha interferon for influenza and viral diseases, which is in the early stage of development; and Oragens for the treatment of viral diseases and disorders of the immune system. Hemispherx Biopharma, Inc. was founded in 1990 and is headquartered in Philadelphia, Pennsylvania. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. William A. Carter M.D, 71
Chairman, Chief Exec. Officer, Chief Scientific Officer, Chairman of Exec. Committee and Member of Strategic Planning Committee |
N/A
| N/A | Mr. Charles T. Bernhardt C.P.A, M.B.A., 48
Chief Financial Officer and Chief Accounting Officer |
N/A
| N/A | Mr. Wayne S. Springate , 38
VP of Operations |
$
150.00K | N/A | Dr. Katalin Ferencz-Biro Ph.D., 62
Sr. VP of Regulatory Affairs and Quality Assurance |
$
145.00K | N/A | Dr. Chaunce Bogard ,
Sr. VP |
N/A
| N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.20% Nasdaq 
0.14%
Profile
